Skip to main content
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. — Investor Relations & Filings

Ticker · ALLO ISIN · US0197701065 US Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country US United States of America
Listing US ALLO

About Allogene Therapeutics, Inc.

https://allogene.com/

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies. The company engineers T cells from healthy donors to create "off-the-shelf" treatments for cancer and autoimmune diseases. This approach is designed to enable on-demand availability, scalability, and reliability, contrasting with autologous therapies that use a patient's own cells. Allogene's pipeline utilizes multiplex gene-engineering and gene-editing capabilities. Its key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma, ALLO-316 for clear cell renal cell carcinoma, and ALLO-329 for autoimmune disease.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or material definitive agreements by a company. The text describes the formation of a joint venture, entry into a material definitive agreement including a Share Purchase Agreement, Shareholders' Agreement, and License Agreement. It does not contain financial statements or detailed financial performance data. The document is not an annual or quarterly report, nor is it an earnings release or audit report. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (9818 characters) and content confirm it is a full filing, not a brief announcement or certification.
2020-12-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events or updates by a company. The text includes detailed clinical trial results and updates on the company's drug development programs, specifically initial Phase 1 results from the UNIVERSAL trial. It is not a full annual or quarterly report, nor is it an earnings release or management discussion. The document is not a proxy, voting result, or governance report. It is a regulatory filing announcing material events and clinical trial data. The length (8659 characters) and content confirm it is a substantive report but not a financial report like 10-K or IR. Therefore, the best classification is Regulatory Filings (RNS), which covers miscellaneous SEC filings like Form 8-K that do not fit other categories.
2020-12-07 English
PRIMARY DOCUMENT
Director's Dealing
2020-11-18 English
10-Q
Interim / Quarterly Report Q3 2020
2020-11-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and references a press release with financial results for the quarter ended September 30, 2020. The document itself does not contain detailed financial statements or comprehensive analysis but rather announces the release of financial results and includes a press release as an exhibit. The document length is 3882 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but not the full earnings release or interim report itself.
2020-11-04 English
8-K/A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, specifically an amendment to a Current Report on Form 8-K. It reports the final voting results of the company's 2020 Annual Meeting of Stockholders held on June 5, 2020. The content includes detailed voting results on director elections, advisory votes on executive compensation frequency, and ratification of the independent auditor. The document is not a full annual report or financial statement but a regulatory filing reporting shareholder voting outcomes. It is not a proxy solicitation or presentation but an official disclosure of voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 6000 characters and contains substantive voting data, not just an announcement of a report publication or certification. Hence, the classification is DVA with high confidence.
2020-10-26 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.